Six solvent fractions isolated from flower bud and leaf ethanolic extracts of Cleistocalyx operculatus were analyzed for their phytochemical contents, including phenolics, flavonoids, saponins, tannins, and alkaloids. Antioxidant activities were measured using the ABTS, DPPH, and FRAP assays. The results showed that the flower bud aqueous fraction (BAF) and the leaf aqueous fraction (LAF) rich in phenolic content (768.18 and 490.74 mg GAE/g dry extract, respectively) exhibited significantly higher antioxidant activities than the other fractions. The flower bud hexane fraction (BHF) had remarkably high flavonoid and saponin contents (134.77 mg QE/g and 153.33 mg OA/g dry extract, respectively), followed by that of the leaf hexane fraction (LHF) (76.54 mg QE/g and 88.25 mg OA/g dry extract, respectively). The BHF and LHF were found to have extremely high antibacterial activity against two H. pylori strains, ATCC 51932 and 43504 (MICs of 125 µg/mL). Interestingly, DMC (2′,4′-Dihydroxy-6′-methoxy-3′,5′-dimethylchalcone) isolated from the BHF displayed greater antibacterial activity against the bacterial strains (MICs of 25–50 µg/mL) than those of the fractions. In addition, DMC presented potent inhibitory effects on H. pylori urease (IC50 of 3.2 µg/mL) and α-amylase (IC50 of 83.80 µg/mL), but no inhibition against α-glucosidase. It was also demonstrated that DMC showed pronounced inhibitory effects on the urease activity and biofilm formation of H. pylori, and could increase the membrane permeability of the bacterial cells. Scanning electron micrographs depicted that the BHF and DMC had strong effects on the cell shape and significantly induced the distortion and damage of the cell membrane. The fractions and DMC showed no significant toxicity to four tested human cell lines. Efforts to reduce antibiotic use indicate the need for further studies of the flower buds and DMC as potential products to prevent or treat gastric H. pylori infections.
Six solvent fractions isolated from flower bud and leaf ethanolic extracts of Cleistocalyx operculatus were analyzed for their phytochemical contents including phenolics, flavonoids, saponins, tannins, and alkaloids. Antioxidant activities were measured using the ABTS, DPPH, and FRAP assays. The results showed that flower bud aqueous fraction (BAF) and leaf aqueous fraction (LAF) rich in phenolic content (768.18 and 490.74 mg GAE/g dry extract, respectively) exhibited significantly higher antioxidant activities than other fractions. Flower bud hexane fraction (BHF) had remarkably high flavonoid and saponin contents (134.77 mg QE/g and 153.33 mg OA/g dry extract, respectively), followed by that of leaf hexane fraction (LHF) (76.54 mg QE/g and 88.25 mg OA/g dry extract, respectively). BHF and LHF were found to have extremely high antibacterial activity against two H. pylori strains ATCC 51932 and 43504 (MICs of 125 µg/ml). Interestingly, DMC (2’,4’-Dihydroxy-6’-methoxy-3’,5’-dimethylchalcone) isolated from BHF displayed greater antibacterial activity against the bacterial strains (MICs of 25–50 µg/ml) than those of the fractions. In addition, DMC presented potent inhibitory effects on H. pylori-urease (IC50 of 3.2 µg/ml) and α-amylase (IC50 of 83.80 µg/ml), but no inhibition against α-glucosidase. It was also demonstrated that DMC showed its pronounced inhibitory effects on urease activity and biofilm formation of H. pylori, and could increase the membrane permeability of the bacterial cells. Scanning electron micrographs depict that BHF and DMC had strong effects on the cell shape and significantly induced distortion and damage of the cell membrane. The fractions and DMC showed no significant toxicity to four tested human cell lines. Efforts to reduce antibiotic use indicate the need for further researches of the flower buds and DMC as potential products to prevent or treat gastric H. pylori infections.
Implanted and indwelling medical devices remain challenged by infection, oxidative stress, and chronic inflammation, underscoring the need for multifunctional surface coatings to holistically address these complications. Peppermint essential oil is inherently antibacterial, antioxidant, and anti‐inflammatory, yet its integration into stable, contact‐active coatings is limited by fabrication constraints. Here, we present a one‐step atmospheric pressure plasma polymerisation process that converts peppermint essential oil into a conformal, cross‐linked coating that preserves precursor‐derived functional groups that drive broad bioactivity. While the coating is substrate‐independent, we evaluate its bioactive performance within the context of bladder catheterisation as a pilot application. It scavenges up to 90% of reactive species, reduces pro‐inflammatory cytokine expression by up to 60%, and increases anti‐inflammatory cytokines by up to 50%, while promoting macrophage polarisation toward an M2 phenotype. The coating exhibits intrinsic antibacterial activity, reducing viable bacteria by 90% (Live/Dead) and 70% (CFUs), attributed to membrane disruption of Gram‐negative pathogens. In turn, this interaction potentiates the activity of colistin and levofloxacin, two antibiotics used in catheter‐associated urinary tract infection management. Together, these findings establish a stable, multifunctional coating capable of mitigating infection, alleviating inflammation, and enhancing antibiotic performance, while offering a sustainable route for essential‐oil‐derived biomaterials.
Controlled antibiotic release from implant surfaces remains a major engineering challenge for preventing early bacterial colonisation while minimising unnecessary drug exposure. Here, we report a solvent-free non-thermal plasma strategy for fabricating ultrathin ε-caprolactone-derived plasma-polymer barrier coatings for enzyme-accelerated antibiotic release. Ester-containing coatings with tunable nanoscale thickness were deposited from ε-caprolactone vapour under argon plasma. Quantum-chemical calculations supported the energetic feasibility of plasma-assisted ε-caprolactone activation, providing a tentative rationale for precursor transformation under plasma-relevant conditions. The coatings showed limited short-term thickness loss under aqueous conditions but underwent accelerated erosion in lipase-containing media. When amoxicillin or vancomycin was loaded beneath a 10 nm plasma-polymer overlayer, the coating reduced passive antibiotic leakage while enabling enzyme-accelerated drug release. The resulting antibiotic-loaded surfaces suppressed bacterial viability and growth in vitro. In a subcutaneous infection model, antibiotic-loaded plasma-polymer-overcoated surfaces reduced bacterial burden and local inflammatory responses compared with infected uncoated and drug-free coating controls. These findings demonstrate the potential of plasma-derived ultrathin polymer barriers as a solvent-free interfacial engineering platform for enzyme-accelerated local antimicrobial delivery.